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Angiogenesis (the recruitment and formation of new blood vessels) may be a limiting step in the growth of tu-
mors. Recent work in animal models of human cancer suggests that even transient angiogenic signals can irre-
versibly block tumor dormancy, promoting tumor growth. Another report concludes that the production of an-
giogenic factors may result from activation of a signaling pathway in the innate immune response. Other
advances include the visualization of the tumor vasculature in living animals and the discovery of an antibody
that has the potential to inhibit tumor angiogenesis by neutralizing a bioactive lipid.
Slumbering Tumors Awaken
Malignant cells that migrate from the primary tumor site often remain as a micrometastasis in a dormant state. The
recruitment of new blood vessels may contribute to the end of tumor dormancy, but the duration of the signal re-
quired for this so-called ‘‘angiogenic switch’’ is not known. Recent work by Indraccolo and colleagues (2006) sug-
gests that only a brief exposure to angiogenic factors is needed to awaken dormant tumors. The authors first estab-
lished a model of tumor dormancy by injecting MOLT-3 human leukemia cells into immunodeficient mice. In this
model, a lack of expression of angiogenic factors by MOLT-3 cells prevents the formation of large tumors, although
small poorly vascularized clusters of MOLT-3 cells were found at injection sites. However, large tumors did develop if
MOLT-3 cells were coinjected with highly angiogenic Kaposi’s sarcoma cells (KS-IMM) that had been irradiated to
arrest their own proliferation. Both normal and irradiated KS-IMM cells expressed angiogenic factors, such as VEGF,
bFGF, and IL-8. Flow cytometry showed that irradiated KS-IMM cells do not persist after four days, suggesting that
their stimulating effect on tumor angiogenesis does not need to be sustained over long periods of time. The authors
propose that even a short-lived alteration in the microenvironment of a dormant tumor, perhaps due to local inflam-
mation, could lead to enhanced tumor angiogenesis and subsequent growth.
In a related study, Naumov et al. (2006) separated angiogenic from nonangio-
genic tumor cell populations by inoculating human breast adenocarcinoma, oste-
osarcoma, and glioblastoma cells into immunodeficient mice. The model that Nau-
mov et al. present for human tumor dormancy is unique because it takes
advantage of the spontaneous switching of nonangiogenic tumor cells to an angio-
genic phenotype. Angiogenic and nonangiogenic cells from each tumor type were
compared for their ability to proliferate in vitro and for their tumorigenicity when re-
injected into immunodeficient mice. Although both angiogenic and nonangiogenic
cell lines proliferated at similar rates in vitro, only the angiogenic lines rapidly de-
veloped palpable tumors in vivo. In contrast, nonangiogenic cells produced micro-
scopic tumors that can remain dormant for many months (see the figure). This
work supports the idea that once the angiogenic switch occurs, it is not switched
off and provides new models with which to test antiangiogenic agents. The inves-
tigators report that bFGF (which promotes angiogenesis) is upregulated in the an-
giogenic tumor cells, whereas thrombospondin-1 (which is antiangiogenic) is
downregulated. Future studies may use this tumor model for genomewide com-
parisons of gene expression to establish the spectrum of differences that characterize the switch from tumor dor-
mancy to the angiogenic phenotype.
S. Indraccolo et al. (2006). Proc. Natl. Acad. Sci. USA 103, 4216–4221. Published online March 6, 2006. 10.1073/
pnas.0506200103.
G.N. Naumov et al. (2006). J. Natl. Cancer Inst. 98, 316–325.
Angiogenesis and the Innate Immune Response
Cross Paths
Activation of the TBK1 signaling pathway, which is part of the innate immune re-
sponse, may trigger the release of proangiogenic factors according to Korherr
and colleagues (2006). These investigators used an automated screening appara-
tus to transfect cells with plasmids from cDNA expression libraries (screening over
250,000 individual plasmids) and harvested the resulting supernatants (see the fig-
ure). Human umbilical vein endothelial cells (HUVEC) were treated with these
supernatants and assayed for proliferation to identify those supernatants with an-
giogenic potential. The screen identified not only known proangiogenic factors—
such as VEGF and FGF1—but also components of a Toll-like receptor (TLR) signal-
ing pathway with angiogenic potential. These TLR signaling components include
TRIF, TBK1, and IRF3. TRIF is an adaptor that binds to TLRs and promotes the
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activation of the kinase TBK1. The transcription factor IRF3 is a substrate of TBK1, and its activation promotes the
transcription of Type 1 interferon genes as part of the innate immune response. The authors also show that TBK1
expression is upregulated in tumors of human breast and colon. Although it is not certain which combination of fac-
tors in the proangiogenic supernatants contribute to proliferation of the endothelial cells, both RANTES and IL-8 (cy-
tokines that increase the proliferation of endothelial cells) are upregulated in supernatants from cells transfected with
TBK1. The search for this cocktail of proangiogenic factors will be aided by the fact that the effect of TBK1 appears to
specifically require IRF3. In contrast, activation of the transcription factor NF-kB, which also acts downstream of
TBK1, although necessary for the effect does not by itself lead to the production of proangiogenic factors. Future
studies may address the question of whether proinflammatory signals or the infection of cells by pathogens stimu-
lates tumor angiogenesis by activating TBK1.
C. Korherr et al. (2006). Proc. Natl. Acad. Sci. USA 103, 4240–4245. Published online March 6, 2006. 10.1073/
pnas.0511319103.
An Antiangiogenic Antibody
Previous work has suggested that sphingosine-1-phosphate (S1P), a secreted lipid, contributes to tumor progres-
sion. Now, Visentin et al. (2006) reveal that S1P may have a particular role in promoting tumor angiogenesis. These
authors show that Matrigel plugs embedded with S1P and then implanted into mice are readily infiltrated by endo-
thelial cells. This effect is similar to that induced by VEGF and bFGF, two well-established proangiogenic factors. The
proangiogenic effect of S1P is blocked when implanted mice are also injected with an anti-S1P monoclonal anti-
body. Moreover, the anti-S1P antibody also appears to block the stimulation of angiogenesis by the growth factors
bFGF and VEGF. The authors suggest that the anti-S1P antibody may have therapeutic potential similar to that of
Avastin, an antibody that inhibits VEGF and was approved in 2004 by the U.S. Food and Drug Administration for
treating colon cancer. Indeed, in several murine models of human cancers, tumors from mice that had been injected
with anti-S1P antibody were smaller and had a lower density of microcapillaries than those from control animals.
Future studies should reveal the mechanisms by which S1P promotes angiogenesis.
B. Visentin et al. (2006). Cancer Cell 9, 225–238.
A Brighter View of the Tumor Vasculature
A new fluorescent probe has been used to visualize the vasculature to a depth of
500 mm beneath the skin of living mouse and chick embryos (Lewis et al., 2006).
To create a particle containing a very high density of fluorescent label, the au-
thors conjugated fluorescent dyes to the cowpea mosaic virus (CPMV).
CPMV has many advantages: It is readily available, inert when injected into an-
imals, and each of the virion’s 60 protein units has 5 surface lysine residues that
react with the reagent that links the fluorophore to the virus. Using chemical
crosslinking, Lewis et al. attained a density of up to 120 fluorophore molecules
per virus particle. They applied their new fluorescent probe to visualizing the tu-
mor vasculature in a chick embryo model of tumor formation. In this model, hu-
man fibrosarcoma cells were injected under the capillary bed of the chick cho-
rioallantoic membrane to form a vascularized tumor. Because dye-labeled
CPMV particles are internalized by endothelial cells, the authors were able to establish a map of the vascular network
(see the figure). Moreover, injection of CPMV particles loaded with a different fluorophore at a later time point allowed
vasculature growth to be studied as the tumors increased in size. In the future, it may be possible to monitor the
growth of a tumor’s vasculature with the infusion of a single type of fluorescent particle. As a step in this direction,
Lewis et al. were able to suppress the internalization of CPMV-fluorophore particles into endothelial cells by coating
them with polyethylene glycol and thus were able to use these particles to visualize both the vascular architecture
and blood flow.
J.D. Lewis et al. (2006). Nat. Med. 12, 354–360. Published online February 26, 2006. 10.1038/nm1368.
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